Qvella announced today that it has completed US$20M in Series B Financing to Fund Clinical Trials,
On-going Research, Team Expansion, and Manufacturing Buildup. New strategic investor bioMérieux will explore collaborative opportunities around Qvella’s Field Activated Sample Treatment (FAST) technology in complementary markets.
Please wait while you are redirected to the right page...
Please share your location to continue.
Check our help guide for more info.